long-term effectiveness of eszopiclone on chronic insomina disorder in middle-aged women

long-term effectiveness of eszopiclone on chronic insomina disorder in middle-aged women - long-term effectiveness of eszopiclone on chronic insomina disorder in middle-aged women

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023690

Enrollment

Registered

2016-10-01

Start date

2016-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

menopausal symptoms/chronic insomnia disorder

Interventions

24-week treatment with 2 mg/day of eszopiclone

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: patients who have subjective insomnia scoring 6 or more on the Athens Insomnia Scale and are diagnosed with chronic insomnia disorder by ICSD-3 defnition

Exclusion criteria

Exclusion criteria: women who are already treated with estrogens, antidepressants, anxiolytics, hypnotics etc. that are supposed to have effects on insomnia symptoms in middle-aged women

Design outcomes

Primary

Measure	Time frame
changes in objective sleep parameters measured by actigraphy after 12 and 24 weeks of treatment	—

Secondary

Measure	Time frame
changes in Pittsburgh Sleep Quality Index, Athens Insomnia Scale, Epworth Sleepiness Scale, St. Marys Hospital Sleep Questionnaire, Menopause Health Related Quality of Life Questionnaire, and Hospital Anxiety and Depression Scale after 12 and 24 weeks of treatment	—

Countries

Japan

Contacts

Public ContactMasakazu Terauchi

Tokyo Medical and Dental University Department of Women's Health

teragyne@tmd.ac.jp03-5803-4605

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026